USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| May 23, 2022 | Mar 2022 | $-0.29 | $-2.40 | $-0.26 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| May 23, 2022 | Mar 2022 | $20.57M | - | $106.62M |
Burning Rock Biotech's next earnings date is Monday, May 23, 2022 for the fiscal quarter ending Mar 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 2 | $-1.01 | $-1.15 | $-0.86 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 0 / 2 | $-0.75 | $-0.75 | $-3.05 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 3 | $107.42M | $91.96M | $121.02M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| May 23, 2022 | Mar 2022 | $-0.38 | - | - |
| Mar 21, 2022 | Dec 2021 | $-1.69 | $-2.40 | -42.01% |
| Nov 16, 2021 | Sep 2021 | $-0.16 | $-0.26 | -59.81% |
| Aug 31, 2021 | Jun 2021 | $-0.15 | $-0.30 | -107.52% |
| May 25, 2021 | Mar 2021 | $-0.14 | $-0.26 | -81.91% |
| Mar 11, 2021 | Dec 2020 | $-0.16 | $-0.23 | -45.77% |
| Nov 20, 2020 | Sep 2020 | $-0.11 | $-0.19 | -69.62% |
| Aug 11, 2020 | Jun 2020 | $-0.20 | $-0.39 | -95.59% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 21, 2022 | Dec 2021 | $-1.10 | $-3.22 | - |
| Mar 11, 2021 | Dec 2020 | $-0.48 | $-0.80 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| May 23, 2022 | Mar 2022 | $20.57M | - | - |
| Mar 21, 2022 | Dec 2021 | $20.89M | - | - |
| Nov 16, 2021 | Sep 2021 | $20.22M | $126.61M | 6.26% |
| Aug 31, 2021 | Jun 2021 | $21.41M | $127.28M | 5.94% |
| May 25, 2021 | Mar 2021 | $19.56M | $106.62M | 5.45% |
| Mar 11, 2021 | Dec 2020 | $19.14M | $131.72M | 6.88% |
| Nov 20, 2020 | Sep 2020 | $18.00M | $123.88M | 6.88% |
| Aug 11, 2020 | Jun 2020 | $13.50M | $106.97M | 7.92% |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 21, 2022 | Dec 2021 | $77.80M | $507.86M | 552.78% |
| Mar 11, 2021 | Dec 2020 | $64.81M | $429.90M | 563.33% |
BNR's next earnings date is Monday, May 23, 2022 for the fiscal quarter ending Mar 31, 2022.
According to analysts, the average EPS estimation for Burning Rock Biotech's next quarterly earnings is $-0.29, with a low EPS estimation of $-0.29, and a high estimation of $-0.29.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 1 downward. The EPS 1 month trend is $-0.27, the last 2 month trend is $-0.27, and the 3 month trend is $-1.50.
Based on analysts, the average revenue estimation is $20.57M, with a low revenue estimation of $20.57M, and a high estimation of $20.57M.
Burning Rock Biotech's previous earnings date was Mar 21, 2022 for its fiscal quarter ended Dec 31, 2021.
BNR's earnings per share (EPS) was $-2.40, missing the consensus analysts forecast of $-1.69 by -42.01%.
The EPS was lower than the previous fiscal quarter (Sep 2021) by 835.67%, and lower than the same period a year before (Dec 2020) by 932.26%.
Free cash flow for the quarter was $-112.35M , compared to $-133.39M last quarter and $-170.20M a year before.
BNR ended the quarter with $86.69M in total debt, a decrease of -14.21% compared to the previous quarter, and an increase of 84.90% compared to the same quarter a year before.
Burning Rock Biotech's previous annual earnings date was Mar 21, 2022 for its fiscal year ended Dec 31, 2021.
BNR's earnings per share (EPS) was $-3.22, missing the consensus analysts forecast of $-1.10 by 192.48% , and lower than the previous year's EPS (Dec 2020) by 299.91%.
Revenues were $507.86M, better than the forecast of $77.80M by 552.78%, and up by 18.13% from previous year's revenue.
The company reported a net income of $-796.70M.
Burning Rock Biotech reported a free cash flow of $-477.89M for its fiscal year, compared to $-153.08M a year ago.
The company ended the fiscal year with $86.69M in total debt, an increase of 84.90% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
